Symbol | Exchange | Currency |
|---|
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has announced positive interim results from a Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-moderate...
Phase 2 Interim Virology Results Indicate Rapid and Sustained Antiviral Activity Against SARS-CoV-2 in Patients with COVID-19 in the Hospitalized SettingAT-527 is Being Studied...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Buy | Buy | Neutral | Sell |
| Technical Indicators | Buy | Buy | Strong Sell | Strong Buy | Sell |
| Summary | Neutral | Buy | Neutral | Buy | Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,660.30 | 2,668.00 | 2,596.00 | +91.9 | +3.58% | 2.08M | ||||
| 369.79 | 375.33 | 357.19 | +18.60 | +5.30% | 33.69M | ||||
| 26.16 | 26.18 | 26.11 | +0.03 | +0.11% | 58.09K | NYSE | |||
| 28.10 | 29.75 | 27.05 | -0.77 | -2.67% | 7.64M | NASDAQ | |||
| 5.28 | 5.34 | 5.28 | +0.020 | +0.38% | 1.33M | NYSE | |||
| 29.52 | 29.90 | 29.03 | -0.10 | -0.34% | 1.11M | NASDAQ | |||
| 6.12 | 6.18 | 6.05 | +0.010 | +0.16% | 18.03M | NYSE | |||
| 138.35 | 139.32 | 137.52 | +0.38 | +0.28% | 1.53M | NYSE | |||
| 20.97 | 20.99 | 20.19 | +0.54 | +2.64% | 1.16M | ||||
| 27.19 | 27.47 | 26.92 | +0.14 | +0.52% | 4.93M | OTC Markets | |||
| 195.58 | 197.00 | 192.50 | -0.36 | -0.18% | 19.57M | NASDAQ | |||
| 57.94 | 57.99 | 56.10 | +1.00 | +1.76% | 548.07K | NASDAQ | |||
| 192.18 | 193.25 | 189.69 | +2.22 | +1.17% | 528.47K | NASDAQ | |||
| 20.57 | 20.57 | 20.57 | +0.17 | +0.83% | 100.00 | OTC Markets | |||
| 192.66 | 193.43 | 190.64 | +1.62 | +0.85% | 1.34M |
Atea Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. It is focused on development of product candidates to treat coronavirus disease (COVID-19), dengue, chronic hepatitis C (HCV), and respiratory syncytial virus (RSV). Its purine nucleotide prodrug platform develops treatments for life threatening diseases caused by single stranded ribonucleic acid (ssRNA) viral infections. Its lead product candidate, AT-527, is an orally administered, antiviral agent for the treatment of patients with COVID-19. It is developing AT-752, an oral, purine nucleoside prodrug product candidate for the treatment of dengue. It is also developing AT-787 for the treatment of chronic HCV infection, including patients with decompensated cirrhosis. It is evaluating AT-889 and other candidates for the treatment of RSV.
